Gryphon Bio

Gryphon Bio is a biotechnology company focused on developing blood-based diagnostic tests for traumatic brain injury (TBI) and other neurological disorders. The company utilizes a proprietary platform to identify and quantify specific protein biomarkers that correlate with brain health and injury severity. Their lead programs aim to provide objective, rapid results to assist clinicians in diagnosing concussions and managing patient recovery. By shifting from subjective assessments to molecular diagnostics, Gryphon Bio seeks to improve outcomes in sports medicine, military health, and emergency care. The technology is designed to be used at the point of care or in clinical laboratory settings to reduce the need for expensive neuroimaging.